| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
We investigated whether Bisabolol has antitumor effects against these cancers. Bisabolol induced a decrease in cell proliferation and viability in cholangiocarcinoma and pancreatic cancer cell lines, but not in pancreatic epithelial cells. Profiling revealed that treatment induced apoptosis and suppressed Akt activation in cholangiocarcinoma. Bisabolol treatment induced the overexpression of early growth response-1 (EGR1). Furthermore, Tumor growth in both subcutaneous and peritoneal xenograft nude mouse models was significantly inhibited by intragastric administration of 1000 mg/kg of Bisabolol, once a week for three weeks. The results indicate thatBisabolol could be a novel therapeutic option for the treatment of cholangiocarcinoma and pancreatic cancer.
|
